GlassScriptPhysician profile
Robert P Spittler
NPI 1891773255
$16,024.66
in general payments reported to CMS, 2019-2025
58 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,192 · 2020: $1,807 · 2021: $2,909 · 2022: $3,219 · 2023: $2,435 · 2024: $2,012 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,897.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,956.35 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Pfizer INC. | $2,016.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,791.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,450.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,149.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $789.90 | 2019-2023 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $699.87 | 2019-2025 | Veozah |
| Lilly USA, LLC | $674.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $468.46 | 2022 | |
| Amarin Pharma, INC. | $420.28 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $400.31 | 2019-2025 | Gardasil 9, Gardasil, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.27 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.05 | 2019-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $203.88 | 2021-2023 | |
| Exact Sciences Corporation | $143.58 | 2023-2025 | Cologuard Collection Kit |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spittler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.